Metastatic prostate cancer proven by 18F-FCH PET/CT staging scan in patient with normal PSA but high PSA doubling time.

Marina Hodolič; Anna Margherita Maffione; Jure Fettich; Borut Gubina; Marino Cimitan; Domenico Rubello

Metastatic prostate cancer proven by 18F-FCH PET/CT staging scan in patient with normal PSA but high PSA doubling time.

Marina Hodolič, Anna Margherita Maffione, Jure Fettich, Borut Gubina, Marino Cimitan, Domenico Rubello

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article › peer-review

Abstract

A 59-year-old man presented with frequent urination. Six months ago, his prostate-specific antigen (PSA) was 1.56 ng/mL; currently it is 3.5 ng/mL (PSA doubling time = 6 months; PSA velocity = 0.19 ng/mL/mo). Biopsy revealed aggressive prostate cancer (Gleason score 5 + 5). Staging with (18)F-fluorocholine PET/CT ((18)F-FCH PET/CT) demonstrated lymph node metastasis. After 6 months of hormonal therapy with goserelin, PSA decreased to 0.38 ng/mL. A (18)F-FCH PET/CT restaging scan demonstrated a global reduction of (18)F-FCH lesion uptake with disappearance of some mediastinal and iliac pelvic lymph node activity.

Original language	English
Pages (from-to)	739-740
Number of pages	2
Journal	Clinical Nuclear Medicine
Volume	38
Issue number	9
Publication status	Published - Sept 2013

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Medicine(all)

Cite this

@article{97503e46f1154005bb21eb022cf0fb0f,

title = "Metastatic prostate cancer proven by 18F-FCH PET/CT staging scan in patient with normal PSA but high PSA doubling time.",

abstract = "A 59-year-old man presented with frequent urination. Six months ago, his prostate-specific antigen (PSA) was 1.56 ng/mL; currently it is 3.5 ng/mL (PSA doubling time = 6 months; PSA velocity = 0.19 ng/mL/mo). Biopsy revealed aggressive prostate cancer (Gleason score 5 + 5). Staging with (18)F-fluorocholine PET/CT ((18)F-FCH PET/CT) demonstrated lymph node metastasis. After 6 months of hormonal therapy with goserelin, PSA decreased to 0.38 ng/mL. A (18)F-FCH PET/CT restaging scan demonstrated a global reduction of (18)F-FCH lesion uptake with disappearance of some mediastinal and iliac pelvic lymph node activity.",

author = "Marina Hodoli{\v c} and Maffione, {Anna Margherita} and Jure Fettich and Borut Gubina and Marino Cimitan and Domenico Rubello",

year = "2013",

month = sep,

language = "English",

volume = "38",

pages = "739--740",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - Metastatic prostate cancer proven by 18F-FCH PET/CT staging scan in patient with normal PSA but high PSA doubling time.

AU - Hodolič, Marina

AU - Maffione, Anna Margherita

AU - Fettich, Jure

AU - Gubina, Borut

AU - Cimitan, Marino

AU - Rubello, Domenico

PY - 2013/9

Y1 - 2013/9

N2 - A 59-year-old man presented with frequent urination. Six months ago, his prostate-specific antigen (PSA) was 1.56 ng/mL; currently it is 3.5 ng/mL (PSA doubling time = 6 months; PSA velocity = 0.19 ng/mL/mo). Biopsy revealed aggressive prostate cancer (Gleason score 5 + 5). Staging with (18)F-fluorocholine PET/CT ((18)F-FCH PET/CT) demonstrated lymph node metastasis. After 6 months of hormonal therapy with goserelin, PSA decreased to 0.38 ng/mL. A (18)F-FCH PET/CT restaging scan demonstrated a global reduction of (18)F-FCH lesion uptake with disappearance of some mediastinal and iliac pelvic lymph node activity.

AB - A 59-year-old man presented with frequent urination. Six months ago, his prostate-specific antigen (PSA) was 1.56 ng/mL; currently it is 3.5 ng/mL (PSA doubling time = 6 months; PSA velocity = 0.19 ng/mL/mo). Biopsy revealed aggressive prostate cancer (Gleason score 5 + 5). Staging with (18)F-fluorocholine PET/CT ((18)F-FCH PET/CT) demonstrated lymph node metastasis. After 6 months of hormonal therapy with goserelin, PSA decreased to 0.38 ng/mL. A (18)F-FCH PET/CT restaging scan demonstrated a global reduction of (18)F-FCH lesion uptake with disappearance of some mediastinal and iliac pelvic lymph node activity.

UR - http://www.scopus.com/inward/record.url?scp=84893788401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893788401&partnerID=8YFLogxK

M3 - Article

C2 - 23816948

AN - SCOPUS:84893788401

SN - 0363-9762

VL - 38

SP - 739

EP - 740

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

IS - 9

ER -

Metastatic prostate cancer proven by 18F-FCH PET/CT staging scan in patient with normal PSA but high PSA doubling time.

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this